Data / Drug companies / Sagent Pharmaceuticals
Sagent Pharmaceuticals: 213 products in the FDA NDC directory, labeler code 25021
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sagent Pharmaceuticals (labeler code 25021) lists 213 products in the FDA National Drug Code Directory, covering 127 finished drugs by generic name. By type: 213 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 16, 2026.
The request: Watch Sagent Pharmaceuticals (FDA labeler code 25021): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 25021
- Products in commercial distribution
- 213
- Packages
- 299
- Finished drugs by generic name
- 127
- Prescription products
- 213
- Over the counter products
- 0
- Controlled substance products
- Schedule II 1, Schedule III 3, Schedule IV 4, Schedule V 1
- Flagged as original packager
- 183 of 183 products that carry the flag
- Started marketing in the last 12 months
- 15
- Products with a marketing end date set
- 3
- Earliest marketing start
- March 24, 2008
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 205 | 96.2% |
| New drug applications (NDA) | 8 | 3.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 213 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 113 | 53.1% |
| Injection, powder, lyophilized, for solution | 46 | 21.6% |
| Injection, powder, for solution | 24 | 11.3% |
| Injection | 14 | 6.6% |
| Solution/ drops | 3 | 1.4% |
| Injection, suspension | 3 | 1.4% |
| Injection, emulsion | 2 | 0.9% |
| Solution | 2 | 0.9% |
| Solution, gel forming / drops | 2 | 0.9% |
| Injection, suspension, liposomal | 1 | 0.5% |
| Kit | 1 | 0.5% |
| Injection, solution, concentrate | 1 | 0.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Zyogreen | 25021-841 | Injection, solution | New drug applications (NDA) | July 16, 2026 |
| Sugammadex | 25021-619 | Injection, solution | Generic drugs (ANDA) | July 1, 2026 |
| Bludigo | 25021-840 | Injection | New drug applications (NDA) | April 15, 2026 |
| Fulvestrant | 25021-471 | Injection, solution | Generic drugs (ANDA) | April 15, 2026 |
| Doxorubicin Hydrochloride Liposome | 25021-263 | Injection, suspension, liposomal | Generic drugs (ANDA) | March 1, 2026 |
| Triamcinolone Acetonide | 25021-054 | Injection, suspension | Generic drugs (ANDA) | March 1, 2026 |
| Diazepam | 25021-618 | Injection, solution | Generic drugs (ANDA) | February 15, 2026 |
| Phytonadione | 25021-505 | Injection, emulsion | Generic drugs (ANDA) | February 1, 2026 |
| Acetazolamide | 25021-839 | Injection, powder, for solution | Generic drugs (ANDA) | January 15, 2026 |
| Ertapenem | 25021-199 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 15, 2026 |
| Timolol Maleate | 25021-009 | Solution, gel forming / drops | Generic drugs (ANDA) | January 15, 2026 |
| Timolol Maleate | 25021-008 | Solution, gel forming / drops | Generic drugs (ANDA) | January 15, 2026 |
| Dorzolamide Hydrochloride | 25021-006 | Solution/ drops | Generic drugs (ANDA) | January 15, 2026 |
| Nicardipine Hydrochloride | 25021-333 | Injection, solution | Generic drugs (ANDA) | January 1, 2026 |
| Carboprost Tromethamine | 25021-477 | Injection, solution | Generic drugs (ANDA) | December 1, 2025 |
| Meropenem | 25021-161 | Injection, powder, for solution | Generic drugs (ANDA) | November 1, 2025 |
| Meropenem | 25021-160 | Injection, powder, for solution | Generic drugs (ANDA) | November 1, 2025 |
| Famotidine | 25021-756 | Injection, solution | New drug applications (NDA) | October 15, 2025 |
| Famotidine | 25021-755 | Injection, solution | New drug applications (NDA) | October 15, 2025 |
| Tranexamic Acid | 25021-415 | Injection, solution | Generic drugs (ANDA) | October 15, 2025 |
| Methocarbamol | 25021-689 | Injection, solution | Generic drugs (ANDA) | October 1, 2025 |
| Polymyxin B | 25021-196 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 1, 2025 |
| Calcitonin Salmon | 25021-473 | Injection, solution | Generic drugs (ANDA) | September 15, 2025 |
| Ertapenem | 25021-199 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 15, 2025 |
| Azithromycin | 25021-180 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 1, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.